HF Foods' Lin on Organic Growth Strategies, M&A: Choppin' It Up
M&A is a great opportunity for HF Foods Group because Asian specialty foodservice distribution is primarily made up of smaller competitors and HF is the only national player in the US, CEO and President Felix Lin tells Bloomberg Intelligence. In this episode of the Choppin' It Up podcast, Lin sits down with BI's senior restaurant and foodservice analyst Michael Halen to discuss the company's plans to grow organically and via acquisitions. He also comments on the new e-commerce platform, competition from Sysco and the impact of tariffs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Tariffs, North Korea Cast Shadow Over Lee's First Day in Office
(Bloomberg) -- South Korea's newly elected President Lee Jae-myung took office with a pledge to revive a national economy threatened by Donald Trump's tariffs just as the US president doubled duties on steel and aluminum, highlighting the pressing challenges facing the Asian leader. Where the Wild Children's Museums Are Billionaire Steve Cohen Wants NY to Expand Taxpayer-Backed Ferry The Global Struggle to Build Safer Cars At London's New Design Museum, Visitors Get Hands-On Access LA City Council Passes Budget That Trims Police, Fire Spending 'We will start by restoring people's livelihoods and reviving the economy,' Lee said at an inauguration ceremony at the National Assembly in Seoul on Wednesday, hours after he won the country's presidential election. 'We will revive the virtuous cycle of the economy by using the national budget as a catalyst.' Lee's first day in office was greeted by Trump's raising of import taxes on steel and aluminum to 50% from 25%. South Korea also faces a 25% across-the-board levy that was later temporarily reduced to 10% for 90 days, in addition to sectoral tariffs imposed on cars, steel and aluminum. Trade talks with the US will provide an early test of Lee's ability to balance foreign policy ties with domestic concerns, with exports equivalent to more than 40% of South Korea's gross domestic product. Lee, who is expected to speak to Trump soon, has said policymakers shouldn't rush into a deal with the US. Lee earlier said he'd 'crawl through Trump's legs if needed' to get a good deal for South Korea. Tuesday's vote was largely seen as a referendum on Lee's ousted predecessor's botched attempt to impose martial law in the longstanding US ally. Lee won the race with 49.4% of the vote, a comfortable victory over the conservative People Power Party's Kim Moon-soo, though not the landslide that looked possible earlier in the year. On the campaign trail, Lee said he would use up to 35 trillion won ($25.4 billion) in a stimulus package if elected to provide aid to households and businesses. That was already an increase from the 30 trillion won figure he started the campaign with. The sense that Lee's administration will be looser on fiscal policy than Yoon Suk Yeol's appeared to ripple through bond markets, pushing the price of 10-year futures on government debt down by more than 100 basis points. Still, stock investors cheered the prospect of a return to political stability and corporate governance reforms. The Kospi Index jumped as much as 2.5% on Wednesday, taking its gain from the April low to more than 20% as investors piled into potential beneficiaries of Lee's reform and growth agenda. In a speech heavy on rhetoric about uniting the nation, Lee also vowed to continue efforts to step up trilateral cooperation with the US and Japan based on a strong alliance with the US and a practical approach to diplomacy. But in a departure from the Yoon administration's hardline stance on North Korea, Lee said South Korea will seek to restore communication channels with North Korea. Any dialogue would take place from a position of strength he said, adding that South Korea's defense budget is twice the size of North Korea's economy. 'No matter how expensive peace is, it is better than war,' Lee said. 'It is better to win without fighting than to win by fighting, and the most reliable security comes from a peace without the need to fight.' The US congratulated Lee on his victory and pledged to continue coordinating security efforts in a bid to modernize their alliance. 'The United States and the Republic of Korea share an ironclad commitment to the Alliance grounded in our Mutual Defense Treaty, shared values, and deep economic ties,' US Secretary of State Marco Rubio said in a statement. 'We will also continue to deepen U.S.-Japan-ROK trilateral cooperation to bolster regional security, enhance economic resilience, and defend our shared democratic principles.' Demonstrating the pressing security challenges facing the new leader, a top security aide to Russian President Vladimir Putin, Sergei Shoigu, arrived in Pyongyang for talks with North Korea's Kim Jong Un, Tass reported Wednesday. Shoigu's visit, following his March trip during which he briefed Kim on US-brokered negotiations to end the war in Ukraine, comes two days after Moscow and Kyiv agreed on a new exchange of prisoners during their second round of peace talks in Istanbul. Shoigu and Kim are set to discuss the situation around Ukraine and bilateral military ties, including 'immortalizing' North Korean troops who fought against Ukraine alongside Russian troops, Interfax said. Kim has emerged as a key ally of Putin since they struck a military treaty a year ago, and his deployment of soldiers raised concerns about the North Korean military's exposure to the real-world and modern combat experience. Lee appointed Wi Sung-lac, a member of his Democratic Party who was once South Korea's top nuclear negotiator with North Korea, as his national security advisor. Lee's top campaign aide and DP lawmaker Kim Min-seok was nominated as the prime minister and Lee Jong-seok, who served as South Korea's unification minister in 2006, was named the country's spy agency chief. --With assistance from Jaehyun Eom, Youkyung Lee and Sanjit Das. (Updates with statement from US Secretary of State Rubio.) YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Millions of Americans Are Obsessed With This Japanese Barbecue Sauce Is Elon Musk's Political Capital Spent? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To Mark Zuckerberg Loves MAGA Now. Will MAGA Ever Love Him Back? ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Asian Value Stocks Trading Below Estimated Worth In June 2025
As global markets navigate the complexities of trade policies and inflationary pressures, Asian economies are experiencing varied impacts, with some regions showing resilience amid these uncertainties. Against this backdrop, identifying undervalued stocks becomes crucial for investors seeking potential opportunities in a fluctuating market environment. Name Current Price Fair Value (Est) Discount (Est) PixArt Imaging (TPEX:3227) NT$219.50 NT$436.79 49.7% cottaLTD (TSE:3359) ¥432.00 ¥860.83 49.8% Zhuhai CosMX Battery (SHSE:688772) CN¥13.36 CN¥26.46 49.5% Dive (TSE:151A) ¥915.00 ¥1819.08 49.7% TLB (KOSDAQ:A356860) ₩17230.00 ₩34141.01 49.5% ALUX (KOSDAQ:A475580) ₩10450.00 ₩20815.81 49.8% China Kings Resources GroupLtd (SHSE:603505) CN¥21.44 CN¥42.38 49.4% BalnibarbiLtd (TSE:3418) ¥1165.00 ¥2301.36 49.4% ikeGPS Group (NZSE:IKE) NZ$0.97 NZ$1.92 49.6% MicroPort CardioFlow Medtech (SEHK:2160) HK$0.87 HK$1.71 49.2% Click here to see the full list of 305 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: Zhongji Innolight Co., Ltd. focuses on the research, development, production, and sales of optical communication transceiver modules and optical devices in China, with a market cap of CN¥101.77 billion. Operations: Zhongji Innolight Co., Ltd. generates revenue primarily from its operations in optical communication transceiver modules and optical devices within the Chinese market. Estimated Discount To Fair Value: 13.7% Zhongji Innolight is trading at CN¥91.76, below its estimated fair value of CN¥106.29, reflecting an undervaluation based on discounted cash flow analysis. Despite recent share price volatility, the company's earnings have grown by nearly 96% over the past year and are expected to continue growing significantly. Revenue growth is projected to surpass both industry and market averages at 20% annually. Recent dividend increases highlight strong cash flow management amidst robust financial performance in Q1 2025. According our earnings growth report, there's an indication that Zhongji Innolight might be ready to expand. Take a closer look at Zhongji Innolight's balance sheet health here in our report. Overview: Zhejiang Tianyu Pharmaceutical Co., Ltd. is involved in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs both in China and internationally, with a market cap of approximately CN¥9.33 billion. Operations: The company's revenue is primarily derived from its activities in the research, development, manufacture, and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) both domestically and internationally. Estimated Discount To Fair Value: 16.2% Zhejiang Tianyu Pharmaceutical's current trading price of CN¥27.14 is below its fair value estimate of CN¥32.38, suggesting it is undervalued based on cash flows. The company has achieved profitability this year, with earnings expected to grow substantially at 42.36% annually, outpacing the market average. Despite recent share price volatility, Q1 2025 results show improved financial performance with net income more than doubling from the previous year, supported by strong revenue growth and a consistent dividend payout strategy. Our comprehensive growth report raises the possibility that Zhejiang Tianyu Pharmaceutical is poised for substantial financial growth. Navigate through the intricacies of Zhejiang Tianyu Pharmaceutical with our comprehensive financial health report here. Overview: Renesas Electronics Corporation is a global company involved in the research, development, design, manufacturing, sales, and servicing of semiconductors across Japan, China, the rest of Asia, Europe, North America, and other international markets with a market cap of ¥3.17 trillion. Operations: The company's revenue is primarily derived from its Automotive segment, which accounts for ¥679.96 billion, followed by the Industrial/Infrastructure/IoT segment at ¥615.96 billion. Estimated Discount To Fair Value: 47.3% Renesas Electronics is trading at ¥1763, significantly below its fair value estimate of ¥3345.4, highlighting its undervaluation based on cash flows. Despite high debt levels and recent share price volatility, the company is poised for substantial earnings growth of 20.3% annually, surpassing market expectations. However, profit margins have decreased from last year's 21.3% to 12.7%. Recent product innovations and strategic expansions in India may bolster future revenue streams and operational capabilities. Our growth report here indicates Renesas Electronics may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Renesas Electronics. Reveal the 305 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:300308 SZSE:300702 and TSE:6723. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
Asian Market Gems: Penny Stock Highlights For June 2025
As the Asian markets navigate a complex landscape of global trade tensions and economic shifts, investors are increasingly seeking opportunities that offer both potential growth and resilience. Penny stocks, though often associated with riskier investments, can still present valuable prospects when grounded in strong financials and clear growth paths. This article explores three such penny stocks in Asia that stand out for their robust balance sheets and potential to thrive amid current market dynamics. Name Share Price Market Cap Financial Health Rating CNMC Goldmine Holdings (Catalist:5TP) SGD0.435 SGD176.3M ★★★★★☆ YKGI (Catalist:YK9) SGD0.102 SGD43.35M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.13 SGD858.72M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.26B ★★★★★★ Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.99 HK$1.66B ★★★★★★ Click here to see the full list of 1,160 stocks from our Asian Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Fu Shou Yuan International Group Limited, with a market cap of HK$8.33 billion, operates in the People's Republic of China providing burial and funeral services through its subsidiaries. Operations: The company's revenue is primarily derived from its burial services at CN¥1.71 billion and funeral services at CN¥339.19 million, with additional contributions from other services totaling CN¥37.44 million. Market Cap: HK$8.33B Fu Shou Yuan International Group, with a market cap of HK$8.33 billion, recently declared a final dividend of HKD 0.0954 per share for 2024, despite facing challenges such as decreased revenue and net income compared to the previous year. The company's profit margins have declined from 30.1% to 18%, reflecting economic pressures and cautious consumer spending in China. While its board is experienced and debt levels are well-managed with more cash than total debt, the management team is relatively new, averaging only 1.8 years in tenure. Earnings are forecasted to grow at nearly 9% annually moving forward. Click here to discover the nuances of Fu Shou Yuan International Group with our detailed analytical financial health report. Gain insights into Fu Shou Yuan International Group's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Lepu Biopharma Co., Ltd. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative anti-tumor targeted therapies and oncology immunotherapies globally, with a market cap of HK$8.13 billion. Operations: The company generates revenue of CN¥367.79 million from the sales of pharmaceutical products and the research and development of new drugs. Market Cap: HK$8.13B Lepu Biopharma, with a market cap of HK$8.13 billion, is navigating the complexities of the biotech sector while remaining pre-revenue. Recent pivotal clinical trial results for MRG003, targeting nasopharyngeal cancer, show promising efficacy and safety compared to chemotherapy. Despite these advancements, the company faces financial challenges with a net loss of CN¥411.38 million in 2024 and high volatility in its share price. Its management team is experienced with an average tenure of 3.2 years, but it grapples with high debt levels and short-term liabilities exceeding its assets by CN¥354.5 million. Navigate through the intricacies of Lepu Biopharma with our comprehensive balance sheet health report here. Gain insights into Lepu Biopharma's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: AIM Vaccine Co., Ltd. focuses on researching, developing, manufacturing, and commercializing vaccine products for human use in the People's Republic of China, with a market cap of HK$4.82 billion. Operations: The company's revenue is primarily derived from the sale of vaccines and research and development services, totaling CN¥1.29 billion. Market Cap: HK$4.82B AIM Vaccine, with a market cap of HK$4.82 billion, is advancing in the biotech sector with innovative mRNA vaccines. The recent dual approval for its mRNA herpes zoster vaccine by the FDA and China's National Medical Products Administration highlights its technological prowess. Despite reporting CN¥1.29 billion in revenue, AIM remains unprofitable with a net loss of CN¥277.23 million in 2024 and faces challenges such as high share price volatility and short-term liabilities exceeding assets by CN¥700 million. However, it benefits from an experienced management team and sufficient cash runway to support ongoing R&D efforts. Dive into the specifics of AIM Vaccine here with our thorough balance sheet health report. Learn about AIM Vaccine's future growth trajectory here. Reveal the 1,160 hidden gems among our Asian Penny Stocks screener with a single click here. Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1448 SEHK:2157 and SEHK:6660. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
